• 1
    Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365: 1687717.
  • 2
    Berry DA, Cirrincione C, Henderson IC et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 2006; 295: 165867.
  • 3
    Henry NL, Hayes DF. Can biology trump anatomy? Do all node-positive patients with breast cancer need chemotherapy? Clin Oncol 2007; 25: 25013.
  • 4
    Frasor J, Stossi F, Danes JM, Komm B, Lyttle CR, Katzenellenbogen BS. Selective estrogen receptor modulators: discrimination of agonistic versus antagonistic activities by gene expression profiling in breast cancer cells. Cancer Res 2004; 64: 152233.
  • 5
    Miller WR, Larionov A. Changes in expression of oestrogen regulated and proliferation genes with neoadjuvant treatment highlight heterogeneity of clinical resistance to the aromatase inhibitor, letrozole. Breast Cancer Res 2010; 12: R52.
  • 6
    Burow ME, Weldon CB, Tang Y, McLachlan JA, Beckman BS. Oestrogen-mediated suppression of tumour necrosis factor alpha-induced apoptosis in MCF-7 cells: subversion of Bcl-2 by anti-oestrogens. J Steroid Biochem Mol Biol 2001; 78: 40918.
  • 7
    Tabuchi Y, Matsuoka J, Gunduz M et al. Resistance to paclitaxel therapy is related with Bcl-2 expression through an estrogen receptor mediated pathway in breast cancer. Int J Oncol 2009; 34: 31319.
  • 8
    Mutoh K, Tsukahara S, Mitsuhashi J, Katayama K, Sugimoto Y. Estrogen-mediated post transcriptional down-regulation of P-glycoprotein in MDR1-transduced human breast cancer cells. Cancer Sci 2006; 97: 1198204.
  • 9
    Li JJ, Weroha SJ, Lingle WL, Papa D, Salisbury JL, Li SA. Estrogen mediates Aurora-A overexpression, centrosome amplification, chromosomal instability, and breast cancer in female ACI rats. Proc Natl Acad Sci USA 2004; 101: 181238.
  • 10
    Alli E, Bash-Babula J, Yang JM, Hait WN. Effect of stathmin on the sensitivity to antimicrotubule drugs in human breast cancer. Cancer Res 2002; 62: 68649.
  • 11
    Ikeda H, Taira N, Hara F et al. The estrogen receptor influences microtubule-associated protein tau (MAPT) expression and the selective estrogen receptor inhibitor fulvestrant downregulates MAPT and increases the sensitivity to taxane in breast cancer cells. Breast Cancer Res 2010; 12: R43.
  • 12
    Lien EA, Lønning PE. Selective oestrogen receptor modifiers (SERMs) and breast cancer therapy. Cancer Treat Rev 2000; 26: 20527.
  • 13
    Obrero M, Yu DV, Shapiro DJ. Estrogen receptor-dependent and estrogen receptor-independent pathways for tamoxifen and 4-hydroxytamoxifen-induced programmed cell death. J Biol Chem 2002; 277: 45695703.
  • 14
    MacCallum J, Cummings J, Dixon JM, Miller WR. Concentrations of tamoxifen and its major metabolites in hormone responsive and resistant breast tumours. Br J Cancer 2000; 82: 162935.
  • 15
    Osborne CK, Wakeling A, Nicholson RI. Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action. Br J Cancer 2004; 90(Suppl. 1): S26.
  • 16
    Robertson JF, Llombart-Cussac A, Rolski J et al. Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study. J Clin Oncol 2009; 27: 45305.
  • 17
    Hug V, Hortobagyi GN, Drewinko B, Finders M. Tamoxifen-citrate counteracts the antitumor effects of cytotoxic drugs in vitro. J Clin Oncol 1985; 3: 16727.
  • 18
    Woods KE, Randolph JK, Gewirtz DA. Antagonism between tamoxifen and doxorubicin in the MCF-7 human breast tumor cell line. Biochem Pharmacol 1994; 47: 144952.
  • 19
    Albain KS, Barlow WE, Ravdin PM et al. Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial. Lancet 2009; 374: 205563.
  • 20
    Pico C, Martin M, Jara C et al. Epirubicin-cyclophosphamide adjuvant chemotherapy plus tamoxifen administered concurrently versus sequentially: randomized phase III trial in postmenopausal node-positive breast cancer patients. A GEICAM 9401 study. Ann Oncol 2004; 15: 7987.
  • 21
    Sertoli MR, Pronzato P, Venturini M et al. A randomized study of concurrent versus sequential adjuvant chemotherapy and tamoxifen in Stage II breast cancer [abstract]. Proc Am Soc Clin Oncol 2002; 21: 182.
  • 22
    Goldhirsch A, Glick JH, Gelber RD et al. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 2005; 16: 156983.
  • 23
    De Vincenzo R, Scambia G, Benedetti Panici P et al. Modulatory effect of tamoxifen and ICI 182,780 on adriamycin resistance in MCF-7 human breast-cancer cells. Int J Cancer 1996; 68: 3408.
  • 24
    Sui M, Huang Y, Park BH, Davidson NE, Fan W. Estrogen receptor alpha mediates breast cancer cell resistance to paclitaxel through inhibition of apoptotic cell death. Cancer Res 2007; 67: 533744.
  • 25
    Sui M, Jiang D, Hinsch C, Fan W. Fulvestrant (ICI 182,780) sensitizes breast cancer cells expressing estrogen receptor alpha to vinblastine and vinorelbine. Breast Cancer Res Treat 2010; 121: 33545.
  • 26
    Taira N, Doihara H, Oota T et al. Gefitinib, an epidermal growth factor receptor blockade agent, shows additional or synergistic effects on the radiosensitivity of esophageal cancer cells in vitro. Acta Med Okayama 2006; 60: 2534.
  • 27
    Kawasaki K, Watanabe M, Sakaguchi M et al. REIC/Dkk-3 overexpression downregulates P-glycoprotein in multidrug-resistant MCF7/ADR cells and induces apoptosis in breast cancer. Cancer Gene Ther 2009; 16: 6572.